Atlas Trials

A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received Long-term Treatment With it Under the Actual Condition of Use

Clinical trial NCT02922543 · COMPLETED

Trial details

NCT number
NCT02922543
Sponsor
Celgene
Status
COMPLETED
Study type
OBSERVATIONAL
Multiple Myeloma
Start date
2011-02-18
Primary completion
2014-10-11
Enrollment
361

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.